Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mac-2 binding protein glycosylation isomer as a novel predictive biomarker for patient survival after hepatitis C virus eradication by DAAs.
Nakagawa M, Nawa N, Takeichi E, Shimizu T, Tsuchiya J, Sato A, Miyoshi M, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Fujiwara T, Watanabe M, Tanaka Y, Asahina Y; Ochanomizu Liver Conference Study Group. Nakagawa M, et al. Among authors: kawai kitahata f. J Gastroenterol. 2020 Oct;55(10):990-999. doi: 10.1007/s00535-020-01715-6. Epub 2020 Aug 8. J Gastroenterol. 2020. PMID: 32770465
Impaired induction of interleukin 28B and expression of interferon λ 4 associated with nonresponse to interferon-based therapy in chronic hepatitis C.
Murakawa M, Asahina Y, Nakagawa M, Sakamoto N, Nitta S, Kusano-Kitazume A, Watanabe T, Kawai-Kitahata F, Otani S, Taniguchi M, Goto F, Nishimura-Sakurai Y, Itsui Y, Azuma S, Kakinuma S, Watanabe M. Murakawa M, et al. J Gastroenterol Hepatol. 2015 Jun;30(6):1075-84. doi: 10.1111/jgh.12902. J Gastroenterol Hepatol. 2015. PMID: 25611696
Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features.
Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Nakagawa M, Tanabe M, Takano S, Fukasawa M, Sakamoto M, Maekawa S, Enomoto N, Watanabe M. Kawai-Kitahata F, et al. J Gastroenterol. 2016 May;51(5):473-86. doi: 10.1007/s00535-015-1126-4. Epub 2015 Nov 9. J Gastroenterol. 2016. PMID: 26553052
Serial measurement of Wisteria floribunda agglutinin positive Mac-2-binding protein is useful for predicting liver fibrosis and the development of hepatocellular carcinoma in chronic hepatitis C patients treated with IFN-based and IFN-free therapy.
Nagata H, Nakagawa M, Nishimura-Sakurai Y, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Goto F, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Tojo N, Tohda S, Asahina Y, Watanabe M; Ochanomizu Liver Conference Study Group. Nagata H, et al. Hepatol Int. 2016 Nov;10(6):956-964. doi: 10.1007/s12072-016-9754-1. Epub 2016 Jul 19. Hepatol Int. 2016. PMID: 27435935
Effect of interferon-based and -free therapy on early occurrence and recurrence of hepatocellular carcinoma in chronic hepatitis C.
Nagata H, Nakagawa M, Asahina Y, Sato A, Asano Y, Tsunoda T, Miyoshi M, Kaneko S, Otani S, Kawai-Kitahata F, Murakawa M, Nitta S, Itsui Y, Azuma S, Kakinuma S, Nouchi T, Sakai H, Tomita M, Watanabe M; Ochanomizu Liver Conference Study Group. Nagata H, et al. J Hepatol. 2017 Nov;67(5):933-939. doi: 10.1016/j.jhep.2017.05.028. Epub 2017 Jun 14. J Hepatol. 2017. PMID: 28627363
Impact of novel NS5A resistance-associated substitutions of hepatitis C virus detected in treatment-experienced patients.
Nitta S, Asahina Y, Kato T, Tsuchiya J, Inoue-Shinomiya E, Sato A, Tsunoda T, Miyoshi M, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Kakinuma S, Hikita H, Takehara T, Watanabe M. Nitta S, et al. Among authors: kawai kitahata f. Sci Rep. 2019 Apr 5;9(1):5722. doi: 10.1038/s41598-019-42114-z. Sci Rep. 2019. PMID: 30952914 Free PMC article.
Efficacy of additional radiofrequency ablation after transcatheter arterial chemoembolization for intermediate hepatocellular carcinoma.
Azuma S, Asahina Y, Nishimura-Sakurai Y, Kakinuma S, Kaneko S, Nagata H, Goto F, Ootani S, Kawai-Kitahata F, Taniguchi M, Murakawa M, Watanabe T, Tasaka-Fujita M, Itsui Y, Nakagawa M, Watanabe M. Azuma S, et al. Hepatol Res. 2016 Apr;46(4):312-9. doi: 10.1111/hepr.12566. Epub 2015 Sep 15. Hepatol Res. 2016. PMID: 26224167
Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System.
Taniguchi M, Tasaka-Fujita M, Nakagawa M, Watanabe T, Kawai-Kitahata F, Otani S, Goto F, Nagata H, Kaneko S, Nitta S, Murakawa M, Nishimura-Sakurai Y, Azuma S, Itsui Y, Mori K, Yagi S, Kakinuma S, Asahina Y, Watanabe M. Taniguchi M, et al. J Clin Transl Hepatol. 2016 Mar 28;4(1):5-11. doi: 10.14218/JCTH.2015.00047. Epub 2016 Mar 15. J Clin Transl Hepatol. 2016. PMID: 27047766 Free PMC article.
Human induced pluripotent stem cell-derived hepatic cell lines as a new model for host interaction with hepatitis B virus.
Kaneko S, Kakinuma S, Asahina Y, Kamiya A, Miyoshi M, Tsunoda T, Nitta S, Asano Y, Nagata H, Otani S, Kawai-Kitahata F, Murakawa M, Itsui Y, Nakagawa M, Azuma S, Nakauchi H, Nishitsuji H, Ujino S, Shimotohno K, Iwamoto M, Watashi K, Wakita T, Watanabe M. Kaneko S, et al. Sci Rep. 2016 Jul 8;6:29358. doi: 10.1038/srep29358. Sci Rep. 2016. PMID: 27386799 Free PMC article.
Hepatic IFNL4 expression is associated with non-response to interferon-based therapy through the regulation of basal interferon-stimulated gene expression in chronic hepatitis C patients.
Murakawa M, Asahina Y, Kawai-Kitahata F, Nakagawa M, Nitta S, Otani S, Nagata H, Kaneko S, Asano Y, Tsunoda T, Miyoshi M, Itsui Y, Azuma S, Kakinuma S, Tanaka Y, Iijima S, Tsuchiya K, Izumi N, Tohda S, Watanabe M. Murakawa M, et al. J Med Virol. 2017 Jul;89(7):1241-1247. doi: 10.1002/jmv.24763. Epub 2017 Feb 27. J Med Virol. 2017. PMID: 28036111
21 results